05:50 AM EDT, 07/16/2026 (MT Newswires) -- Circio Holding (CRNA.OL) formed a research collaboration with Avenue Biosciences to improve long-term expression of secreted proteins. The Norway-listed biotechnology company, which is focused on developing novel circular RNA expression technology for gene and cell therapy, said in a Thursday release that the expression of secreted proteins is relevant for the treatment of a wide range of diseases. Avenue Biosciences will utilize its protein engineering platform to identify signal peptides that allow an improved secretion of therapeutic proteins expressed by Circio's circVec platform.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.